Values First Advisors Inc. Has $2.19 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Values First Advisors Inc. trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,113 shares of the biopharmaceutical company's stock after selling 879 shares during the quarter. Alnylam Pharmaceuticals comprises 1.3% of Values First Advisors Inc.'s portfolio, making the stock its 16th largest holding. Values First Advisors Inc.'s holdings in Alnylam Pharmaceuticals were worth $2,189,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $243,000. Jones Financial Companies Lllp bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $63,000. Assetmark Inc. boosted its stake in Alnylam Pharmaceuticals by 9.2% during the 4th quarter. Assetmark Inc. now owns 10,033 shares of the biopharmaceutical company's stock valued at $2,361,000 after purchasing an additional 847 shares in the last quarter. Atria Investments Inc boosted its stake in Alnylam Pharmaceuticals by 5.3% during the 4th quarter. Atria Investments Inc now owns 3,311 shares of the biopharmaceutical company's stock valued at $779,000 after purchasing an additional 166 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock valued at $45,570,000 after purchasing an additional 192,916 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 1.7%

Alnylam Pharmaceuticals stock traded down $5.33 during mid-day trading on Friday, hitting $317.32. 343,064 shares of the company's stock were exchanged, compared to its average volume of 893,457. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The stock has a market cap of $41.37 billion, a P/E ratio of -151.83 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $333.70. The stock has a 50 day moving average of $300.06 and a two-hundred day moving average of $268.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) earnings per share. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 price target for the company. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $343.39.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer directly owned 48,948 shares of the company's stock, valued at $14,899,281.72. This represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.